×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
Yahoo Finance
SAN DIEGO, April 29, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to...
4 hours ago
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024,...
5 days ago
Acadia Pharma’s stock falls 15% after failed drug trial
MarketWatch
One of Acadia Pharma's drugs failed to meet goals of a late-stage trial about a schizophrenia treatment.
1 month ago
Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short
Investopedia
Key Takeaways · Acadia Pharmaceuticals' drug missed endpoints for treating schizophrenia patients, news that sent Acadia shares sharply lower.
1 month ago
The top emerging pharmaceutical companies in the US
Pharmaceutical Technology
From Organon & Co to Denali Therapeutics, Pharmaceutical Technology lists the top ten emerging US pharmaceutical companies in 2023 based on...
6 days ago
Acadia to end Nuplazid testing after schizophrenia trial flop and years of failed expansion efforts
Fierce Pharma
Acadia Pharmaceuticals is calling it quits on future testing of Nuplazid after a string of expansion efforts have come up short.
1 month ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors...
1 week ago
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been ...
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for...
1 week ago
Analysts Have Made A Financial Statement On ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Yearly Report
Yahoo Finance
ACADIA Pharmaceuticals is also expected to turn profitable, with statutory earnings of US$0.62 per share. Before this earnings report, the...
1 month ago
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of ...
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett...
2 weeks ago